Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1/2 Study…
First clinical data on safety and activity of NTLA-2002, Intellia’s second systemically administered in vivo CRISPR candidate CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) --…